AGM/EGMJul 1, 2026, 07:06 AM
RedHill Biopharma Reschedules AGM to Aug 6; Adds New Proposal
AI Summary
RedHill Biopharma Ltd. has rescheduled its Annual General Meeting of Shareholders from July 28, 2026, to August 6, 2026. This change was made to furnish updated proxy materials that include an additional proposal for shareholder consideration. The AGM agenda includes the re-appointment of auditors, the re-election of two directors, the approval of Dror Ben-Asher's engagement as Chairman and CEO, and an amendment to eliminate the par value of the company's shares. Shareholders will also review the financial statements for the fiscal year ended December 31, 2025.
Key Highlights
- Annual General Meeting (AGM) rescheduled from July 28, 2026, to August 6, 2026.
- Rescheduling due to updated proxy materials including an additional shareholder proposal.
- Shareholders to vote on re-appointment of Kesselman & Kesselman as auditors for 2026.
- Proposal to re-elect Mr. Rick D. Scruggs and Dr. Shmuel Cabilly as directors for three-year terms.
- Approval sought for Mr. Dror Ben-Asher to serve as Chairman and CEO for a three-year period.
- Proposal to amend the Company’s Articles of Association to eliminate the par value of shares.
- Record date for voting at the General Meeting is July 2, 2026.
Price Impact
More from RDHL